Kimberly Maersk-Moller Sells 4,106 Shares of MiMedx Group, Inc. (NASDAQ:MDXG) Stock

MiMedx Group, Inc. (NASDAQ:MDXG - Get Free Report) insider Kimberly Maersk-Moller sold 4,106 shares of the company's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $7.89, for a total value of $32,396.34. Following the completion of the sale, the insider now directly owns 310,836 shares in the company, valued at $2,452,496.04. This trade represents a 1.30 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Kimberly Maersk-Moller also recently made the following trade(s):

• On Friday, February 28th, Kimberly Maersk-Moller sold 2,111 shares of MiMedx Group stock. The stock was sold at an average price of $8.40, for a total transaction of $17,732.40.

MiMedx Group Trading Down 1.5 %

NASDAQ:MDXG traded down $0.12 on Tuesday, reaching $7.92. The stock had a trading volume of 366,929 shares, compared to its average volume of 696,579. MiMedx Group, Inc. has a 12-month low of $5.47 and a 12-month high of $10.14. The company has a market cap of $1.17 billion, a price-to-earnings ratio of 14.40 and a beta of 1.97. The firm's fifty day moving average is $8.44 and its two-hundred day moving average is $7.83. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The company reported $0.07 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.07. The business had revenue of $92.91 million for the quarter, compared to the consensus estimate of $89.42 million. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. Equities analysts expect that MiMedx Group, Inc. will post 0.3 EPS for the current fiscal year.

Remove Ads

Analyst Ratings Changes

Separately, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $13.00 target price on shares of MiMedx Group in a research note on Thursday, February 27th.

Institutional Investors Weigh In On MiMedx Group

A number of hedge funds and other institutional investors have recently made changes to their positions in MDXG. First Light Asset Management LLC purchased a new stake in MiMedx Group in the 4th quarter valued at about $32,168,000. Norges Bank acquired a new stake in shares of MiMedx Group in the fourth quarter worth approximately $4,020,000. JPMorgan Chase & Co. grew its holdings in MiMedx Group by 133.1% in the fourth quarter. JPMorgan Chase & Co. now owns 693,106 shares of the company's stock valued at $6,668,000 after purchasing an additional 395,739 shares during the period. Meros Investment Management LP acquired a new position in MiMedx Group during the fourth quarter worth approximately $3,801,000. Finally, Arrowstreet Capital Limited Partnership raised its stake in MiMedx Group by 484.2% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 362,481 shares of the company's stock worth $3,487,000 after purchasing an additional 300,433 shares during the period. Hedge funds and other institutional investors own 79.15% of the company's stock.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.